Association Between Rs1862513 and Rs3745367 Genetic Polymorphisms of Resistin and Risk of Cancer: A Meta-Analysis

Overview

Journal Asian Pac J Cancer Prev

Specialty Oncology

Date 2018 Oct 27

PMID 30360595

Citations 6

Authors

Mohammad Hashemi

Gholamreza Bahari

Farhad Tabasi

Abdolkarim Moazeni-Roodi

Saeid Ghavami

Affiliations

Soon will be listed here.

Abstract

The present study aimed to assess any associations between resistin gene (RETN) polymorphisms and cancer susceptibility by conducting a meta-analysis. A comprehensive literature search was performed with PubMed, Web of Science, Scopus and Google Scholar for relevant studies published before April 2018. For the rs1862513 polymorphism, data from 9 studies covering 1,951 cancer patients and 2,295 healthy controls were included in this meta-analysis. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Our meta-analysis revealed that this RETN polymorphism significantly increased the risk of cancer in codominant (OR=1.23, 95% CI= 1.01-1.50, p=0.04, CG vs CC; and OR=1.25, 95% CI= 1.03-1.53, p=0.03, GG vs CC), dominant (OR=1.19, 95% CI= 1.05-1.35, p=0.006, CG+GG vs CC), and allele (OR=1.14, 95% CI= 1.00-1.30, p=0.04, G vs C) inheritance genetic models. Stratification analysis by cancer type revealed that the rs1862513 variant significantly increased the risk of colorectal and breast cancer, and that cancer overall in Caucasians (OR=1.22, 95% CI= 1.04-1.43, p=0.02, CG+GG vs CC; OR=1.18, 95% CI= 1.04-1.34, p=0.01, G vs C). The data revealed no correlation between the rs3745367 polymorphism and cancer risk. Further well-designed studies with larger sample sizes and different ethnicities are warranted to validate the present findings.

Citing Articles

Decoding Resistin Gene Polymorphisms: Implications for Lung Cancer Risk and Clinical Outcomes of Platinum-Based Chemotherapy.

Gong W, Huang D, Zhou T, Zhu X, Huang Y, Lv Y Biomedicines. 2025; 13(2).

PMID: 40002704 PMC: 11852191. DOI: 10.3390/biomedicines13020291.

An Updated Review of Resistin and Colorectal Cancer.

Rompou A, Bletsa G, Tsakogiannis D, Theocharis S, Vassiliu P, Danias N Cureus. 2024; 16(7):e65403.

PMID: 39184804 PMC: 11344879. DOI: 10.7759/cureus.65403.

Updated Clinical Evidence on the Role of Adipokines and Breast Cancer: A Review.

Verras G, Tchabashvili L, Chlorogiannis D, Mulita F, Argentou M Cancers (Basel). 2023; 15(5).

PMID: 36900364 PMC: 10000674. DOI: 10.3390/cancers15051572.

Association between Genetic Polymorphisms of miR-1307, miR- 1269, miR-3117 and Breast Cancer Risk in a Sample of South East Iranian Women.

Sarabandi S, Sattarifard H, Kiumarsi M, Karami S, Taheri M, Hashemi M Asian Pac J Cancer Prev. 2021; 22(1):201-208.

PMID: 33507700 PMC: 8184203. DOI: 10.31557/APJCP.2021.22.1.201.

Association between genetic polymorphisms of long noncoding RNA H19 and cancer risk: a meta-analysis.

Hashemi M, Moazeni-Roodi A, Sarabandi S, Karami S, Ghavami S J Genet. 2019; 98.

PMID: 31544800

References

Schoen R, Tangen C, Kuller L, Burke G, Cushman M, Tracy R . Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999; 91(13):1147-54. DOI: 10.1093/jnci/91.13.1147. View

Lichtenstein P, Holm N, Verkasalo P, Iliadou A, Kaprio J, Koskenvuo M . Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343(2):78-85. DOI: 10.1056/NEJM200007133430201. View

Steppan C, Bailey S, Bhat S, Brown E, Banerjee R, Wright C . The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818):307-12. DOI: 10.1038/35053000. View

Shuldiner A, Yang R, Gong D . Resistin, obesity, and insulin resistance--the emerging role of the adipocyte as an endocrine organ. N Engl J Med. 2002; 345(18):1345-6. DOI: 10.1056/NEJM200111013451814. View

Cho Y, Youn B, Chung S, Kim K, Lee H, Yu K . Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia. 2004; 47(3):559-565. DOI: 10.1007/s00125-003-1319-x. View

Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H . The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet. 2004; 75(4):678-86. PMC: 1182055. DOI: 10.1086/424761. View

Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A . Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005; 174(9):5789-95. DOI: 10.4049/jimmunol.174.9.5789. View

John B, Irukulla S, Abulafi A, Kumar D, Mendall M . Systematic review: adipose tissue, obesity and gastrointestinal diseases. Aliment Pharmacol Ther. 2006; 23(11):1511-23. DOI: 10.1111/j.1365-2036.2006.02915.x. View

Giovannucci E . Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2008; 86(3):s836-42. DOI: 10.1093/ajcn/86.3.836S. View

10.

Wagsater D, Mumtaz M, Lofgren S, Hugander A, Dimberg J . Resistin in human colorectal cancer: increased expression independently of resistin promoter -420C > G genotype. Cancer Invest. 2008; 26(10):1008-14. DOI: 10.1080/07357900802087267. View

11.

Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E . Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis. 2008; 24(3):275-81. DOI: 10.1007/s00384-008-0605-y. View

12.

Pechlivanis S, Lorenzo Bermejo J, Pardini B, Naccarati A, Vodickova L, Novotny J . Genetic variation in adipokine genes and risk of colorectal cancer. Eur J Endocrinol. 2009; 160(6):933-40. DOI: 10.1530/EJE-09-0039. View

13.

Guadagni F, Roselli M, Martini F, Spila A, Riondino S, DAlessandro R . Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res. 2009; 29(8):3321-7. View

14.

Gonullu G, Kahraman H, Bedir A, Bektas A, Yucel I . Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis. 2009; 25(2):205-12. DOI: 10.1007/s00384-009-0828-6. View

15.

Nakajima T, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S . Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 2010; 101(5):1286-91. PMC: 11159666. DOI: 10.1111/j.1349-7006.2010.01518.x. View

16.

Al-Harithy R, Al-Ghafari A . Resistin in human colon cancer. Increased expression independently of resistin promoter C-180G genotype. Saudi Med J. 2010; 31(5):495-500. View

17.

Salageanu A, tucureanu C, Lerescu L, Caras I, Pitica R, Gangura G . Serum levels of adipokines resistin and leptin in patients with colon cancer. J Med Life. 2011; 3(4):416-20. PMC: 3019064. View

18.

Danese E, Montagnana M, Minicozzi A, Bonafini S, Ruzzenente O, Gelati M . The role of resistin in colorectal cancer. Clin Chim Acta. 2012; 413(7-8):760-4. DOI: 10.1016/j.cca.2012.01.019. View

19.

Dalamaga M, Sotiropoulos G, Karmaniolas K, Pelekanos N, Papadavid E, Lekka A . Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin Biochem. 2013; 46(7-8):584-90. DOI: 10.1016/j.clinbiochem.2013.01.001. View

20.

Joshi R, Lee S . Obesity related adipokines and colorectal cancer: a review and meta-analysis. Asian Pac J Cancer Prev. 2014; 15(1):397-405. DOI: 10.7314/apjcp.2014.15.1.397. View